1. Edmonds CJ, Hayes S, Kermode JC, Thompson BD. Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. Br J Radiol. 1977. 50:799–807.
2. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998. 338:297–306.
3. Mazzaferri EL, Kloos RT. Braverman LE, Utiger RD, editors. Carcinoma of follicular epithelium: Radioiodine and other treatments and outcomes. Werner and Ingbar's the thyroid. 2005. 9th ed. Pliladelphia: Lippincott Williams & Wilkins;934–966.
4. DeGroot LJ, Larsen PR, Hennemann G. The thyroid and its diseases. 1996. 6th ed. New York: Churchill Livingstone Inc;635–696.
5. Hilts SV, Hellman D, Anderson J, Woolfenden J, Van Antwerp J, Patton D. Serial TSH determination after T3 withdrawal or thyroidectomy in the therapy of thyroid carcinoma. J Nucl Med. 1979. 20:928–932.
6. Grigsby PW, Siegel BA, Bekker S, Clutter WE, Moley JF. Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation. J Nucl Med. 2004. 45:567–570.
7. Serhal DI, Nasrallah MP, Arafah BM. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. J Clin Endocrinol Metab. 2004. 89:3285–3289.
8. Goldberg LD, Ditchek NT. Thyroid carcinoma with spinal cord compression. JAMA. 1981. 245:953–954.
9. Woodmansee WW, Haugen BR. Uses for recombinant human TSH in patients with thyroid cancer and nodular goiter. Clin Endocrinol (Oxf). 2004. 61:163–173.
10. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 2005. 12:49–64.
11. Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. J Clin Endocrinol Metab. 2001. 86:5148–5151.
12. Vargas GE, Uy H, Bazan C, Guise TA, Bruder JM. Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. J Clin Endocrinol Metab. 1999. 84:3867–3871.
17. Salvatori M, Perotti G, Rufini V, Maussier ML, Dottorini M. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan? Clin Endocrinol (Oxf). 2004. 61:704–710.
18. Schlumberger M, Charbord P, Fragu P, Gardet P, Lumbroso J, Parmentier C, Tubiana M. Relationship between thyrotropin stimulation and radioiodine uptake in lung metastases of differentiated thyroid carcinoma. J Clin Endocrinol Metab. 1983. 57:148–151.
19. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2002. 87:4063–4068.
20. Park JT 2nd, Hennessey JV. Two-week low iodine diet is necessary for adequate outpatient preparation forradioiodine rhTSH scanning in patients taking levothyroxine. Thyroid. 2004. 14:57–63.
21. Tomoda C, Uruno T, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, Amino N, Kuma K, Miyauchi A. Reevaluation of stringent low iodine diet in outpatient preparation for radioiodine examination and therapy. Endocr J. 2005. 52:237–240.